In its first few months, Pfizer’s Velsipity has already made a splash in the ulcerative colitis space, where it’s up against fellow S1P Zeposia.
Everest Medicines Announces Acceptance of VELSIPITY® NDA in Macau
Pfizer inflammatory bowel disease drug wins EU approval
Pfizer`s Velsipity (etrasimod) Receives Approval in Europe
Pfizer’s S1P receptor modulator for treating ulcerative colitis, etrasimod, which was at the center of a billion-dollar buyout from Arena Pharma, has now taken another step forward.
Pfizer has laid out the detailed results behind its boast that etrasimod — the S1P receptor modulator at the center of its $6.7 billion buyout of Arena Pharma — is the winner of the class, potentially leapfrogging an earlier entrant from Bristol Myers Squibb.
SHANGHAI, May 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) presented at Digestive Disease Week (DDW) 2022 detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluating etrasimod, a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately-to-severely active ulcerative colitis (UC).
Pfizer’s etrasimod showed improvement in patients with moderate-to-severe ulcerative colitis after 52 weeks. It met the twin main goals of statistically significant improvement in remission at week 12 and week 52 compared to placebo.